ReviewAnnals of hematology2025

Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.

Hanna Löffler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.